BioNTech counts on shift to cancer drugs after second quarter losses quadruple

Losses at German drugmaker BioNTech (22UAy.DE) quadrupled in the second quarter from a year earlier, the company said on Monday, as it banks on a strategy shift towards new cancer treatments following a sharp drop-off in sales of its COVID-19 vaccine.